“Big money” Positions

In Q4 2018 Nuvasive Inc (NASDAQ:NUVA) big money sentiment increased to 1.38, according to Securities and Exchange Commission filings. So its up 0.37, from 2018Q3’s 1.01. 132 hedge funds increased or opened new positions, while 96 cut down and sold their equity positions in Nuvasive Inc so the sentiment is more positive. These funds own 53.17 million shares, that’s up from 52.52 million shares in 2018Q3. Funds holding Nuvasive Inc in top 10 changed to 3 from 5 for a decrease of 2. In total 31 funds closed positions, 65 reduced and 80 increased. Also 52 funds bought new Nuvasive Inc stakes.

Significant Nuvasive Inc Investors

Sector Gamma As owns 473,923 shares in Nuvasive Inc as of Q4 2018. Nuvasive Inc’s shareholder Sg Capital Management Llc owns 225,041 shares as of Q4 2018. Hood River Capital Management Llc reported 682,313 shares. Anchor Capital Advisors Llc revealed 921,269 shares position in Nuvasive Inc. The Maryland-based fund Profit Investment Management Llc holds 38,961 shares or 1.75% of their long stock exposure.

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery.The firm is worth $3.00 billion. The Company’s products focus on applications for spine fusion surgery, including biologics used for spinal fusion process.241.96 is the P/E ratio. The companyÂ’s principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

NUVA reached $58.07 during the last trading session after $0.75 change.NuVasive, Inc. has 881,971 shares volume, 4.51% up from normal. NUVA is uptrending and has moved 22.20% since March 10, 2018. NUVA outperformed by 17.83% the S&P 500.

NuVasive, Inc. (NASDAQ:NUVA)’s earnings release is anticipated by WallStreet on May, 7, as reported by Faxor. This year’s EPS analyst estimate is anticipated to be $0.42. That is 7.69 % up compareed to $0.39 EPS for last year. NUVA’s profit could hit $21.68M if the current EPS of $0.42 is accurate. After $0.69 EPS was revealed previous quarter, analysts now see negative EPS growth of -39.13 % for NuVasive, Inc..

Metropolitan Life Insur New York has 29,766 shs. First Allied Advisory Svcs Inc has invested 0.01% in NuVasive, Inc. (NASDAQ:NUVA). Jane Street Gru Lc has invested 0% in NuVasive, Inc. (NASDAQ:NUVA). Martingale Asset Mgmt L P owns 4,409 shs. Vaughan Nelson Inv Mngmt Lp invested in 317,865 shs. 4,411 are owned by Hartford Inv Mgmt. The Illinois-based Hightower Advsrs Ltd Liability Co has invested 0.01% in NuVasive, Inc. (NASDAQ:NUVA). Advsr Asset Mgmt accumulated 0.02% or 17,667 shs. Hsbc Public Limited Co owns 85,084 shs or 0.01% of their US capital. 518,863 are held by Rothschild And Asset Management Us. Synovus Fincl Corporation has 88 shs for 0% of their capital. Amer Century holds 126,268 shs. Tudor Investment Et Al reported 78,253 shs stake. Great West Life Assurance Can holds 0% of its capital in NuVasive, Inc. (NASDAQ:NUVA) for 30,606 shs. Phocas Fin reported 97,075 shs.

NuVasive, Inc. registered $464,318 net activity with 0 insider purchases and 2 sales since November 16, 2018.

NuVasive, Inc. (NASDAQ:NUVA) Ratings Coverage

A total of 12 analysts rate NuVasive (NASDAQ:NUVA) as follows: 7 “Buy”, 4 “Hold” and 1 “Sell”. Тherefore 58% are bullish. (NASDAQ:NUVA) has 18 ratings reports on 10 Mar 2019 according to StockzIntelligence. On Tuesday, September 25 the firm has “Equal-Weight” rating by Morgan Stanley given. On Thursday, September 27 the firm has “Outperform” rating by Robert W. Baird given. The stock rating was downgraded by Needham to “Hold” on Friday, February 8. On Wednesday, October 31 Morgan Stanley maintained NuVasive, Inc. (NASDAQ:NUVA) rating. Morgan Stanley has “Equal-Weight” rating and $73 target. On Tuesday, February 12 the company was downgraded by Jefferies. On Wednesday, February 20 the firm has “Buy” rating given by BTIG Research. On Wednesday, February 20 the firm earned “Hold” rating by Cantor Fitzgerald. On Monday, September 17 Canaccord Genuity maintained the shares of NUVA in report with “Buy” rating. In Tuesday, January 8 report UBS maintained the stock with “Sell” rating. On Wednesday, January 2 the rating was maintained by Morgan Stanley with “Equal-Weight”.

For more NuVasive, Inc. (NASDAQ:NUVA) news posted briefly go to: Seekingalpha.com, Fool.com, Seekingalpha.com, Nasdaq.com or Benzinga.com. The titles are as follows: “NuVasive up 25% after hours on interest from Smith & Nephew – Seeking Alpha” posted on February 08, 2019, “Why NuVasive, Avis Budget Group, and Insperity Jumped Today – Motley Fool” on February 11, 2019, “NuVasive and OHR Pharmaceutical among healthcare gainers; Celldex Therapeutics leads the losers – Seeking Alpha” with a publish date: February 11, 2019, “Health Care Sector Update for 02/11/2019: ALGN,NUVA,NVCN,ACB,ACB.TO – Nasdaq” and the last “26 Stocks Moving In Monday’s Pre-Market Session – Benzinga” with publication date: February 11, 2019.